{"id":"leuplin-or-zoladex","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"50-70","effect":"Erectile dysfunction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"5-15","effect":"Injection site reaction"},{"rate":"5-10","effect":"Headache"},{"rate":"variable","effect":"Bone density loss (osteoporosis)"},{"rate":"5-10","effect":"Gynecomastia"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs bind to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by downregulation and sustained suppression of these hormones. This results in castration-level testosterone suppression in males and estrogen suppression in females, making them effective for hormone-dependent cancers and certain reproductive disorders.","oneSentence":"Leuprolide and goserelin are GnRH agonists that suppress luteinizing hormone and follicle-stimulating hormone, leading to suppression of testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:35.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Breast cancer (premenopausal women)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT07158021","phase":"PHASE2","title":"Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-01-22","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":75},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT05498272","phase":"PHASE2","title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","status":"RECRUITING","sponsor":"Rana McKay, MD","startDate":"2023-02-01","conditions":"Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation","enrollment":32},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT02454543","phase":"NA","title":"Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martini-Klinik am UKE GmbH","startDate":"2015-05","conditions":"Prostate Cancer","enrollment":452},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05241860","phase":"PHASE2","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-11-21","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":79},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT02023463","phase":"PHASE1","title":"Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2014-04-02","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer","enrollment":25},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT05625087","phase":"PHASE2","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-19","conditions":"Breast Cancer Stage IV","enrollment":162},{"nctId":"NCT06199986","phase":"NA","title":"DeADT - Living Well With Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05333328","phase":"PHASE4","title":"OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","status":"RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2023-02-06","conditions":"Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":418},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer","enrollment":19},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT00544830","phase":"PHASE2","title":"Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-18","conditions":"PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":29},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":146},{"nctId":"NCT06050109","phase":"","title":"The Benefits of Continued Use of Ovarian Function Suppression After 5 Years","status":"RECRUITING","sponsor":"Hongmei Zheng, PhD","startDate":"2023-09-01","conditions":"Breast Cancer Female, Endocrine Therapy","enrollment":1200},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT02588404","phase":"","title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT04657679","phase":"PHASE4","title":"Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2021-05-20","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":960},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT00099086","phase":"PHASE1","title":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-01-16","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT06177015","phase":"PHASE3","title":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-11","conditions":"Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy","enrollment":200},{"nctId":"NCT03664895","phase":"PHASE3","title":"Density Lowering Effect of \"OFS Add on to TMX\"(DELFINO Trial)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-09-03","conditions":"Breast Cancer Invasive","enrollment":224},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT02941926","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-30","conditions":"Breast Cancer","enrollment":3246},{"nctId":"NCT04465097","phase":"PHASE2","title":"Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-07-08","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT01377389","phase":"PHASE2","title":"Ipilimumab + Androgen Depravation Therapy in Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-17","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT02221999","phase":"PHASE2, PHASE3","title":"Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2013-09","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer","enrollment":250},{"nctId":"NCT00651326","phase":"PHASE3","title":"Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-06-02","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT00664456","phase":"PHASE3","title":"Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Prostate Cancer","enrollment":421},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":"Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I","enrollment":57},{"nctId":"NCT00771017","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-07","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02058706","phase":"PHASE2","title":"LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2014-05","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":71},{"nctId":"NCT03969121","phase":"PHASE3","title":"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer","status":"COMPLETED","sponsor":"Kyoto Breast Cancer Research Network","startDate":"2019-07-16","conditions":"Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":141},{"nctId":"NCT00430183","phase":"PHASE3","title":"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2007-05-08","conditions":"Prostate Cancer","enrollment":788},{"nctId":"NCT02914158","phase":"PHASE3","title":"Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-03-30","conditions":"Breast Cancer","enrollment":680},{"nctId":"NCT01717053","phase":"PHASE2","title":"Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-01-17","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT03279250","phase":"PHASE2","title":"Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":86},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT00005044","phase":"PHASE3","title":"Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-02","conditions":"Prostate Cancer","enrollment":1579},{"nctId":"NCT05304169","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","startDate":"2017-11-14","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT05212857","phase":"PHASE2","title":"Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-04","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00116220","phase":"PHASE3","title":"Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"1995-09","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT00003653","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1999-01-05","conditions":"Prostate Cancer","enrollment":1386},{"nctId":"NCT04622761","phase":"PHASE2","title":"Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome","status":"NOT_YET_RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2021-01-15","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT00970203","phase":"PHASE2","title":"Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-09","conditions":"Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate","enrollment":13},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT02472275","phase":"PHASE1","title":"PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-06","conditions":"Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":8},{"nctId":"NCT02059213","phase":"PHASE2","title":"A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT02168062","phase":"PHASE2","title":"Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-06-16","conditions":"Prostate Adenocarcinoma","enrollment":57},{"nctId":"NCT02742675","phase":"PHASE2","title":"Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":418,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Leuplin or zoladex","genericName":"Leuplin or zoladex","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide and goserelin are GnRH agonists that suppress luteinizing hormone and follicle-stimulating hormone, leading to suppression of testosterone and estrogen production. Used for Advanced prostate cancer, Breast cancer (premenopausal women), Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}